News | February 24, 2026
Zelluna gets green light for first-in-human trial of groundbreaking TCR-NK cancer therapy
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
The clinical program has benefited from extensive European Union support, including the IMI2 TRIC-TB and UNITE4TB projects, as well as funding from the EDCTP2 bEto-TB project
The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control
PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
